Plain-English translation of NCT06501053 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new way to treat early-stage rectal cancer using a combination of two types of radiation therapy. One group will receive the standard treatment: a longer course of radiation plus (capecitabine). The other group will receive a shorter radiation course plus a focused radiation boost called contact brachytherapy, without . The goal is to see if the shorter, -free approach works just as well while causing fewer side effects.
Doctors want to find a way to treat rectal cancer that is less burdensome for patients. The new treatment removes and shortens the overall treatment time, which could mean fewer side effects and a better quality of life — but researchers need to confirm it works just as well as the standard approach.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two treatment groups. Both groups will receive a focused radiation boost (contact brachytherapy) delivered in 3 sessions over 4 weeks. The standard group will also receive 5 weeks of longer-course radiation with taken on radiation days. The experimental group will receive a shorter, 1-week course of radiation with no . You will be monitored closely during treatment and followed up afterward to track how well the cancer responds and how you are feeling.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Sweden
Sponsor
Alexander Valdman
Collaborators
Uppsala University Hospital, Karolinska Institutet
Enrollment target
~110 participants
Started
March 2025
Primary completion
April 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Alexander Valdman, MD, PhD
Alexander Valdman
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.